Peter Hauptig

Peter Hauptig has extensive experience in the biopharmaceutical industry. Peter is currently working as a Project Director at Calliditas Therapeutics AB since 2022. Prior to that, they served as the Global Project Director at Oncopeptides AB from 2020 to 2022.

From 2014 to 2020, Peter worked at Sobi - Swedish Orphan Biovitrum AB (publ). Peter held the positions of Senior Program Director from 2018 to 2020 and Program Director Haemophilia from 2014 to 2018. As Program Director Haemophilia, they led the launch preparations and launch of Sobi's haemophilia assets in the EMENAR region. Peter also provided operational leadership for the Humanitarian Aid Donation Program collaboration.

Before joining Sobi, Peter worked at CMC Biologics A/S (now AGC Biologics) as the Director of Upstream Process Development from 2013 to 2014. Peter also served as a CMC Project Manager at Swedish Orphan Biovitrum from 2010 to 2013, where they were responsible for upstream and downstream manufacturing process development and regulatory documentation.

Peter's earlier experience includes working as a Project Manager at Biovitrum AB from 2006 to 2010, where they managed the development of manufacturing processes and regulatory communications. Peter was also a Project Leader for cell culture development and manufacturing at Biovitrum AB from 2001 to 2006.

Peter started their career as a Project Leader for cell culture process development at Pharmacia Corp. from 2000 to 2001. Peter began gaining experience in the biotech/chemistry field as a Summer Trainee at The Swedish Patent and Registration Office in 1998, where they performed prior art search and assessed patentability for biotech/chemistry patent applications.

Peter Hauptig attended Linköping University from 1995 to 2000, where they pursued a degree in Biotechnology. Peter successfully graduated from the university with a Master of Science in Civil Engineering (M.Sc. (Civ. Ing.)).